LeMaitre Vascular, Inc. (LMAT) fair value analysis
Nasdaq · Updated 2026-10-19
LMAT price how computed
Forward Fair Value verdict
UndervaluedLMAT is trading at more than a 25% discount to estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $80.82
- Sector
- Healthcare
- 12-month range
- $78.80–$117.39
- Market cap
- $1.85B
- From 52-week high
- -31.2%
- Shares outstanding
- 22.9M
- Rank in Healthcare by discount to fair value
- #14 of 108
Last price is our stored weekly price from 2026-10-16, older than the 2026-10-19 run that built this page; the chart runs through 2026-10-16.
LeMaitre Vascular, Inc. is a medical device company that develops, manufactures, and markets vascular access products, vascular interventional tools, and related devices used in vascular surgery and interventional radiology procedures. The company operates globally, with a presence in North America, Europe, and other international markets.
LMAT currently ranks #14 of 108 Healthcare stocks by discount to fair value. It has screened as Undervalued for 14 consecutive weekly runs.
Fundamentals (4 quarters) how computed
- Market cap
- $1.85B
- P/E (trailing)
- 28x
- Revenue (TTM)
- $262M
- Net margin
- 25.0%
- EPS (TTM)
- $2.85
- Gross margin
- 72.1%
- Debt / equity
- 0.45
- Revenue growth (3-yr avg)
- 16.2%
- Shares outstanding
- 22.9M
Derived indicators how computed
- Quality grade
- A
- Margin trend
- Expanding
- 52-week position
- The bottom quarter of its range
- DCF cross-check
- Overvalued
Technicals how computed
- RSI (14-day)
- 52 · neutral
- 50-day average
- $80.92
- 200-day average
- $94.45
- Moving-average state
- 50-day below 200-day (death cross state); price below both averages
Dividends how computed
- Paid, last 12 months
- $0.95 per share (4 payments)
- Yield on last price
- 1.18%
- Consecutive years of increases
- 14
- Last ex-dividend date
- 2026-08-20
- Last payment date
- 2026-09-03
Earnings how computed
- Next earnings report
- 2026-11-04 (post-market)
- Last 8 quarters vs consensus
- 5 beat, 2 missed
- Quarter by quarter
- 2026-06 ▼ miss (-8.6%)
2026-03 ▲ beat (+3.0%)
2025-12 ▲ beat (+3.0%)
2025-09 ▲ beat (+33.9%)
2025-06 ▲ beat (+5.3%)
2025-03 ▼ miss (-4.0%)
2024-12 ▬ met (0.0%)
2024-09 ▲ beat (+14.0%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 4 buy · 4 hold · 0 sell (8 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $107
- Target vs last price
- +32.4%
What our data shows for LMAT
- Our model validated 17 trailing price-to-earnings windows for LMAT, built from quarterly earnings records.
- Shares are trading in the lower third of their 12-month price range of $78.80–$117.39.
- The 14-day relative strength index sits at a neutral 52.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for LMAT
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent LMAT news
TickrTrends' derived news-sentiment signal for LMAT is currently leaning positive, computed from recent coverage.
- Copeland Capital Management, LLC Adds to NAPCO Security Technologies Inc (NSSC) -- Shares Look 19% Undervalued on GF Value (gurufocus.com, 2026-10-15)
TickrTrends take: I cannot write this response because the headline provided is about NSSC (NAPCO Security Technologies), not LMAT, and you've asked me to relate news about LMAT to its valuation context while only using facts given. The headline contains no information about LMAT, making it impossible to connect the two as instructed without inventing data. - Copeland Capital Management, LLC Trims Excelerate Energy Inc (EE) Stake -- Shares Look 18% Undervalued on GF Value (gurufocus.com, 2026-10-15)
TickrTrends take: I cannot complete this request as written because the headline concerns Excelerate Energy Inc (EE), not LMAT, and I have no facts provided about LMAT's business, financials, or current valuation metrics. Connecting an EE news item to LMAT's valuation context would require me to invent data or make unsupported assumptions, which violates your instruction to use only given facts. To write accurate prose for this task, I would need factual information about LMAT's current financials, valuation ratios, or relevant company developments. - LeMaitre Will Announce Third Quarter 2026 Earnings Results on November 4, 2026 (manilatimes.net, 2026-10-12)
TickrTrends take: LeMaitre Vascular will report its third quarter 2026 results on November 4, 2026, providing an opportunity for investors to assess the company's recent operational performance against current market pricing. Given TickrTrends' undervalued designation for LMAT, the earnings announcement will be a key moment to evaluate whether the healthcare company's financial results support or challenge that valuation assessment. Readers focused on valuation should monitor revenue trends, profitability metrics, and management guidance to determine if the current market price appropriately reflects LeMaitre's business fundamentals and growth trajectory.
More LMAT news
- LeMaitre Vascular: The Q2 Miss Hides A Stronger Acquisition Machine (NASDAQ:LMAT) (seekingalpha.com, 2026-10-01)
- Speculative Rally Weighed on LeMaitre Vascular (LMAT) (finance.yahoo.com, 2026-09-01)
What people are saying
Follow the LMAT conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is LMAT stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), LMAT is trading at more than a 25% discount to estimated fair value and screens as undervalued. The exact fair value and discount are available to subscribers.
What is LMAT's TickrTrends verdict?
LMAT's current verdict is Undervalued, refreshed with every weekly Forward Fair Value run.
How does LMAT compare to other Healthcare stocks?
LMAT ranks #14 of 108 Healthcare stocks in TickrTrends' coverage by discount to fair value.
Is LMAT overbought or oversold?
LMAT's 14-day RSI is in neutral territory - neither overbought nor oversold.
Does LMAT pay a dividend?
Yes. LMAT paid $0.95 per share over the last twelve months (4 payments), a 1.18% yield on TickrTrends' last price, and has raised the annual total for 14 consecutive years. The last ex-dividend date was 2026-08-20.
When does LMAT report earnings next?
LMAT's next earnings report is scheduled for 2026-11-04 (post-market), per the published earnings calendar.
Does LMAT usually beat earnings estimates?
Over its last 8 reported quarters LMAT beat the consensus estimate 5 times and missed 2 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about LMAT?
Of 8 analysts covering LMAT, 4 rate it a buy, 4 a hold and 0 a sell - buy-leaning, with a consensus price target of $107 (+32.4% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.
More in Healthcare
Head-to-head comparisons
LMAT vs DXCM · LMAT vs EMBC · LMAT vs HQY · LMAT vs INDV · LMAT vs LLY